Claris Lifesciences, a Rs.760 crore plus pharmaceutical company from Ahmedabad, has received setback during the first quarter ended March 2012 due to flat growth in sales and higher input costs. Its consolidated net profit declined by 28.6 per cent ... PharmaBiz, 1 week ago
Claris Lifesciences Q1 net down 28% - Business Standard, 1 week ago
Claris Lifesciences Q4 cons revenue at Rs1822mn - India Infoline, 1 week ago
See all (9) images for "claris lifesciences"
Consolidated EBITDA is at Rs 541 million Claris Lifesciences announced its un-audited financial results for the quarter ended March 31, 2013 at its recently held board meeting in Mumbai. The consolidated revenues for the quarter stood at Rs 1,822 ...Express Pharma, 1 week ago Claris Lifesciences - Limited Review for March 31, 2013 SBICAP Securities, 1 week ago Claris Lifesciences - Financial Results for March 31, 2013 SBICAP Securities, 1 week ago Healthcare-focused investor OrbiMed buys stake in Claris Lifesciences VC Circle, 1 month ago
Claris Lifesciences has informed BSE that the Board of Directors of the Company at its meeting held on May 10, 2013, inter alia, have considered and approved the resignation tendered by Mr. Rajesh Kumar Modi as the Company Secretary and Compliance Officer of ...Money Control, 1 week ago Claris Lifesciences - Outcome of Board Meeting SBICAP Securities, 1 week ago Claris Lifesciences board recommends dividend Money Control, 2 months ago
Mumbai, May 10 : Claris Lifesciences Ltd., a leading sterile injectables pharmaceutical company, on Friday announced its un-audited financial results for the quarter ended 31st March, 2013 at its board meeting held at Mumbai.New Kerala, 1 week ago Claris Lifesciences receives ANDA approval for Metroprolol Tartrate Injection in US Indian-Commodity, 2 weeks ago Claris Lifesciences gets USFDA drug approval Economic Times, 2 weeks ago Claris gets USFDA nod for hypertension drug Business Standard, 2 weeks ago
Claris Lifesciences' promoter Aditya Sushil Kumar Handa has sold around 12 lakh shares amounting to 1.85% stake for over Rs 23 crore. Handa has offloaded 11,80,120 shares on an average price of about Rs 200 per share in the company through open ...Indian-Commodity, 1 month ago Caduceus Capital buys 10.65 lakh shares of Claris Life Money Control, 1 month ago Claris promoter sells 12 lakh shares for over Rs 23 cr Business Line, 1 month ago Claris promoter sells 12L shares for over Rs 23 cr Economic Times, 1 month ago
More from: , Smart Investor...and 2 other sources
Kirit Kanjaria is appointed as company secretary and compliance officer of Claris Lifesciences with effect from 13 April 2013. Powered by Capital Market - Live News News Analyst Videos Archive New to site? Advantages » Important Links HDFC Group ...HDFC Securities, 1 week ago Claris Life change in compliance officer Money Control, 1 month ago Claris Lifesciences - Change in Compliance Officer SBICAP Securities, 1 month ago Claris Lifesciences re-appoints director Money Control, 1 month ago
Net profit of Claris Lifesciences declined 13.66% to Rs 1.39 crore in the quarter ended March 2013 as against Rs 1.61 crore during the previous quarter ended March 2012. Sales rose 1.97% to Rs 155.62 crore in the quarter ended March 2013 as against ...HDFC Securities, 1 week ago Claris Life consolidated Dec '12 sales at Rs 194.75 crore Money Control, 2 months ago
|SBICAP Securities, 1 month ago Claris Life fixes book closure for dividend AGM Money Control, 1 month ago|
Claris Lifesciences Limited (533288) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new company profile report
Claris Lifesciences Limited (Claris) is a pharmaceutical company, based in India. It manufactures and distributes nutritional preparations, sterile injectables and hospital products. The company's products include anesthesia, nutrition, plasma ...TransWorldNews, 4 days ago Claris Lifesciences Limited: Company Profile - New SWOT Report TransWorldNews, 4 weeks ago
Claris Lifesciences Ltd. (CLAR) may be the next takeover target among Indian injectable-drug producers as a shortage of medicines in the U.S. prompts buyers to seek companies with approved manufacturing facilities. Claris could fetch more than ...BioSpace, 2 months ago Drug Deficit Turning Indias Claris Into Target: Real M Oncology Business Review, 2 months ago
on your WebpageAdd Widget >Get your members hooked!